The FSH Society has awarded a grant for a second year of support for the FSHD Clinical Trials Research Network (CTRN), through the coordinating center based at the University of… Read More »
$133,254 awarded to FSHD Clinical Trials Research Network
FSH Society awards $690,894 in new research grants
A drug that helps muscles grow and regenerate. Molecules that occur naturally in our cells to repress DUX4, the “toxic gene” thought to cause FSHD. A deeper dive into why… Read More »
Facio selects first series of potential drug development candidates
We are sharing this news release from Facio, the Netherlands-based biotech founded by FSHD advocates and business leaders with the sole mission of developing treatments for FSHD. In this story,… Read More »
Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
We are sharing the following press release from Acceleron Pharma, Inc., regarding the progress of their Phase 2 clinical trial of ACE-083. The FSH Society collaborates with Acceleron to help… Read More »
Video: Molecular therapy for FSH muscular dytrophy
In this FSH Society webinar, Scott Q. Harper, PhD, of Nationwide Children’s Research Institute describes FSHD genetics and explains how gene and molecular therapy could be used to block the… Read More »